Program - Innovation Theatre: Animal models support new modality drug discovery and development

Innovation Theatre: Animal models support new modality drug discovery and development

Tuesday, July 14, 2026

10:30 AM - 11:00 AM

Details

New modality drugs sales occupy >80% of top 10 best-selling drugs sales in 2025. Eli Lilly’s GLP-1 drug tirzepatide is projected to generate more than 45 billion sales in 2026. New modality drugs including biologics, siRNA/ASO, TPD/MG, CAR-T, etc offer targeted therapy, long duration of effects and potential less side effects. The trend will continue since there’s a robust pipeline of innovative new modality therapies being developed and will continue drive their market share. At WuXi AppTec, we quickly adapt to these changes, we not only develop integrated solutions for these new modality drugs, specially for peptide drugs, Protac/MG and siRNA/ASO, etc we also develop tailed solutions to quickly move our client projects forward. At this talk, we will highlight our integrated solution from target discovery/validation, ADME/PK assessment, efficacy and toxicology assessment to commercialization of different modality drugs. We mainly focus on several cases studies how we achieve these goals in a very efficient manner.

Speaker

Li Fugang (Frank)

Executive Director

Wuxi Biology

Presenter

Biography

Dr. Fugang (Frank) Li is a distinguished leader in animal models and drug discovery and development, boasting over 25 years of experience in biopharmaceutical research and animal model development in the United States and China. Prior to joining Wuxi AppTec, he held key positions at Amgen, Bayer and Eli Lilly in the U.S. Dr. Li has successfully spearheaded multiple innovative drug development projects that have advanced to clinical trials and received approval. At WuXi AppTec, the pharmacology team under his leadership collaborates closely with 13 of the top 15 global pharmaceutical companies, as well as numerous emerging biotech firms. Their work spans various disease areas, including obesity/diabetes, liver/kidney/lung diseases and fibrosis, inflammation and autoimmune diseases, pain, and central nervous system diseases, etc. Many of these projects have successfully transitioned into clinical trial and several of them into clinical practice.